Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1bPhil McEwan, Hiromitsu Kumada, Thomas Ward et al.|Value in Health Regional Issues|2014Cited by 16
Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphomaJennifer L. Crombie, Anupama Kalsekar, Monika Jun et al.|Leukemia & lymphoma/Leukemia and lymphoma|2024Cited by 6
A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimensKristine Broglio, Scott Berry, Eric S. Daar et al.|Journal of Comparative Effectiveness Research|2015Cited by 4
Determining Comparative Effectiveness Benchmarks for Emerging Treatments for Hepatitis C Virus (Hcv) Infection in the Single Arm Study Design SettingKristine Broglio, Scott Berry, Melanie Quintana et al.|Value in Health|2014Cited by 2
P1144 DETERMINING THE COMPARATIVE EFFECTIVENESS OF EMERGING TREATMENT REGIMENS FOR HEPATITIS C VIRUS (HCV) INFECTION FROM SINGLE ARM PHASE III TRIALSMelanie Quintana, Scott Berry, Kristine Broglio et al.|Journal of Hepatology|2014Cited by 2